为您找到相关结果约500个

你是不是要搜索 期刊嗜血细胞综合征诊断专家共识+ALK阴性间变性大细胞淋巴瘤诊断专家共识 点击跳转

ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms

CMTR1-ALK: an ALK fusion in a patient with no response to ALK inhibitor crizotinib

Sequential ALK Inhibitors Can Select for Lorlatinib-Resistant Compound ALK Mutations in ALK-Positive

ALK Inhibitors in the Treatment of ALK Positive NSCLC

Response to ALK-TKIs in a lung adenocarcinoma patient harboring dual DCTN1-ALK and ALK-CLIP4 rearrangements

Concomitant novel ALK-SSH2, EML4-ALK and ARID2-ALK, EML4-ALK double-fusion variants and confer sensitivity

PI3Kβ inhibition enhances ALK-inhibitor sensitivity in ALK-rearranged lung cancer

Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity

EML4-ALK Variant Affects ALK Resistance Mutations

MPRIP-ALK, a Novel ALK Rearrangement That Responds to ALK Inhibition in NSCLC

Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-targetALK inhibitors in neuroblastoma

Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC

Brigatinib: A Review in ALK-Inhibitor Naive Advanced ALK-Positive NSCLC

An advanced NSCLC patient with ALK-RNF144A and HIP1-ALK fusions treated with ALK-TKI combination therapy

Changing ALK-TKI-Resistance Mechanisms in Rebiopsies of ALK-Rearranged NSCLC: ALK- and BRAF-Mutations

为您找到相关结果约500个

共500条页码: 1/34页15条/页